<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017537</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068700</org_study_id>
    <secondary_id>UAB-0020</secondary_id>
    <secondary_id>NCI-G01-1955</secondary_id>
    <nct_id>NCT00017537</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer</brief_title>
  <official_title>Phase IB Trial of Active Specific Immunotherapy With MVF-HER-2(628-647) and CRL1005 Copolymer Adjuvant in Patients With Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who
      have metastatic or recurrent cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the optimum biologic dose of MVF-HER-2(628-647)-CRL 1005 vaccine
      that will induce anti-HER-2 antibody in patients with metastatic or recurrent cancer. II.
      Characterize the nature and severity of toxicity of this drug in these patients. III.
      Document any clinical responses to this drug in these patients.

      OUTLINE: This is a dose-escalation study. Patients receive MVF-HER-2(628-647)-CRL 1005
      vaccine intramuscularly on days 1 and 29. Cohorts of 5 patients receive escalating doses of
      MVF-HER-2(627-647)-CRL 1005 vaccine until at least 2 of 5 patients experience dose-limiting
      toxicity. Patients are followed on days 43 and 57 and every 2 months for at least 1 year.

      PROJECTED ACCRUAL: Approximately 5-25 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the optimum biologic dose of MVF-HER-2 (628-647)-CRL 1005 vaccine that will induce snit-HER-2 antibody in patients with metastatic or recurrent cancer</measure>
    <time_frame>baseline to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the nature and severity of toxicity of this drug in these patients.</measure>
    <time_frame>baseline to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Document any clinical responses to this drug in these patients.</measure>
    <time_frame>baseline to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Dose #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose #1 administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose #2 administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose #3 administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose #4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose #4 administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose #5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered dose #5</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVF-HER-2(628-647)-CRL 1005 vaccine</intervention_name>
    <arm_group_label>Dose #1</arm_group_label>
    <arm_group_label>Dose #2</arm_group_label>
    <arm_group_label>Dose #3</arm_group_label>
    <arm_group_label>Dose #4</arm_group_label>
    <arm_group_label>Dose #5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed metastatic and/or recurrent solid tumor,
        especially the following: Breast Ovarian Non-small cell lung cancer Gastric adenocarcinoma
        No standard therapy available No brain metastases

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:
        Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3
        Hepatic: Bilirubin no greater than 1.5 mg/dL ALT less than 2 times upper limit of normal No
        hepatitis A, B, or C Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance
        greater than 60 mL/min Cardiovascular: No serious cardiopulmonary disorder No congestive
        heart failure No symptomatic coronary artery disease No serious cardiac arrhythmia
        Pulmonary: No serious cardiopulmonary disorder No symptomatic chronic obstructive pulmonary
        disease Immunologic: Reactive to at least 1 of the following skin test antigens: Candida,
        mumps, Trichophyton, intermediate strength PPD, tetanus toxoid No concurrent disease
        requiring corticosteroids or other immunosuppressive drugs No autoimmune disease, including
        rheumatoid arthritis, systemic lupus erythematosus, scleroderma,
        polymyositis-dermatomyositis, or vasculitic syndrome No prior anaphylactic response to
        other vaccine No hypersensitivity to MVF-HER-2(628-647) Other: No active HIV No active
        infection requiring antibiotic therapy No serious medical disease Not pregnant or nursing
        Negative pregnancy test Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy and
        recovered Chemotherapy: At least 4 weeks since prior cytotoxic chemotherapy and recovered
        Endocrine therapy: At least 4 weeks since prior hormonal therapy and recovered No
        concurrent corticosteroids Radiotherapy: At least 4 weeks since prior radiotherapy and
        recovered Surgery: At least 4 weeks since prior surgery and recovered No prior splenectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre L. Triozzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2004</study_first_posted>
  <last_update_submitted>August 2, 2013</last_update_submitted>
  <last_update_submitted_qc>August 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

